168 related articles for article (PubMed ID: 35440696)
1. 3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth.
Shukla S; Fletcher S; Chauhan J; Chalfant V; Riveros C; Mackeyev Y; Singh PK; Krishnan S; Osumi T; Balaji KC
Cancer Gene Ther; 2022 Nov; 29(11):1550-1557. PubMed ID: 35440696
[TBL] [Abstract][Full Text] [Related]
2. Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization.
Chauhan J; Wang H; Yap JL; Sabato PE; Hu A; Prochownik EV; Fletcher S
ChemMedChem; 2014 Oct; 9(10):2274-2285. PubMed ID: 24976143
[TBL] [Abstract][Full Text] [Related]
3. Beta-catenin represses protein kinase D1 gene expression by non-canonical pathway through MYC/MAX transcription complex in prostate cancer.
Nickkholgh B; Sittadjody S; Rothberg MB; Fang X; Li K; Chou JW; Hawkins GA; Balaji KC
Oncotarget; 2017 Oct; 8(45):78811-78824. PubMed ID: 29108267
[TBL] [Abstract][Full Text] [Related]
4. The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth.
Shukla S; Riveros C; Al-Toubat M; Chardon-Robles J; Osumi T; Serrano S; Kase AM; Petit JL; Meurice N; Gleba J; Copland JA; Chauhan J; Fletcher S; Balaji KC
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568667
[TBL] [Abstract][Full Text] [Related]
5. Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding.
Macek P; Cliff MJ; Embrey KJ; Holdgate GA; Nissink JWM; Panova S; Waltho JP; Davies RA
J Biol Chem; 2018 Jun; 293(24):9301-9310. PubMed ID: 29695509
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
Struntz NB; Chen A; Deutzmann A; Wilson RM; Stefan E; Evans HL; Ramirez MA; Liang T; Caballero F; Wildschut MHE; Neel DV; Freeman DB; Pop MS; McConkey M; Muller S; Curtin BH; Tseng H; Frombach KR; Butty VL; Levine SS; Feau C; Elmiligy S; Hong JA; Lewis TA; Vetere A; Clemons PA; Malstrom SE; Ebert BL; Lin CY; Felsher DW; Koehler AN
Cell Chem Biol; 2019 May; 26(5):711-723.e14. PubMed ID: 30880155
[TBL] [Abstract][Full Text] [Related]
7. Cellular experiments to study the inhibition of c-Myc/MAX heterodimerization.
Singh A; Sharma S; Kumar P; Garg N
Methods Enzymol; 2022; 675():193-205. PubMed ID: 36220270
[TBL] [Abstract][Full Text] [Related]
8. The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities.
Montagne M; Beaudoin N; Fortin D; Lavoie CL; Klinck R; Lavigne P
PLoS One; 2012; 7(2):e32172. PubMed ID: 22384171
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
Clausen DM; Guo J; Parise RA; Beumer JH; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
J Pharmacol Exp Ther; 2010 Dec; 335(3):715-27. PubMed ID: 20801893
[TBL] [Abstract][Full Text] [Related]
10. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
11. Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding.
Park S; Chung S; Kim KM; Jung KC; Park C; Hahm ER; Yang CH
Biochim Biophys Acta; 2004 Feb; 1670(3):217-28. PubMed ID: 14980448
[TBL] [Abstract][Full Text] [Related]
12. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
13. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
14. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells.
Grinberg AV; Hu CD; Kerppola TK
Mol Cell Biol; 2004 May; 24(10):4294-308. PubMed ID: 15121849
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore identification of c-Myc inhibitor 10074-G5.
Yap JL; Wang H; Hu A; Chauhan J; Jung KY; Gharavi RB; Prochownik EV; Fletcher S
Bioorg Med Chem Lett; 2013 Jan; 23(1):370-4. PubMed ID: 23177256
[TBL] [Abstract][Full Text] [Related]
16. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
18. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
[TBL] [Abstract][Full Text] [Related]
19. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
20. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
